Any current/future new fundraising through debt or equity?

Current CAPEX of approximately Rs. 140 crores is being funded with a debt-to-internal accrual ratio of 2:1 (about 66.7% debt and 33.3% internal accruals). No explicit mention of new equity fundraising in the call. Greenfield expansion CAPEX delayed due to commodity price inflation; equipment ordering postponed to Nov 2022 with completion expected by early 2024 and commercial production ramp-up from FY25. Given the existing debt funding for the CAPEX and the deferred schedule, no immediate new fundraising beyond planned debt is indicated. Management did not explicitly mention plans for

Any current/future capex/capital investment/strategic investment?

NGL Fine-Chem is undertaking a greenfield expansion project at Tarapur. Original CAPEX estimate was Rs. 100 crores, revised to Rs. 140-150 crores due to inflation in raw material and steel prices. Equipment ordering for the greenfield expansion was initially scheduled for May 2022 but delayed to November 2022 due to high commodity prices. The new facility construction is expected to complete in early 2024, with commercial production ramp-up anticipated by Q2 FY25. The expansion is expected to increase capacity by approximately 60%, adding potential revenue of around Rs. 200 crores. CAPEX fundi

Future growth expectations in sales/revenue/volumes?

NGL Fine-Chem plans to expand its product portfolio to about 30 APIs by 2024 from around 22-23 currently. The market size for current products is approximately Rs. 1,500 crores, expected to grow to Rs. 2,300-2,500 crores with planned new products. Three new products in trial runs are anticipated to increase market size by Rs. 800-1,000 crores. Additional new products planned for this year and next 2-3 years will further expand the market opportunity. Sales volume growth has been impacted recently due to high prices and demand suppression but is expected to recover by Q4 of the current year. Ca

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue growth expected from addition of 3 new products, potentially increasing market size by ₹800-1,000 crores (Page 14). Plan to expand product portfolio to 30 APIs by 2024, with new products contributing to market expansion (Pages 12-13). Capacity expansions delayed due to cost overruns and inflation; new greenfield CAPEX expected to complete in early 2024, ramping up revenues from FY25 (Pages 5-6, 10). Return on capital expected to remain stable over a 3-5 year horizon despite near-term challenges (Page 13). Current demand and margin pressure expected to ease gradually; gross margins may

IN US

Sale is live|00:00:00left today

NGL Fine Chem LtdQ2 FY22Pharmaceuticals & Biotechnology

NGL Fine Chem Ltd Q2 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹3,054P/E: 48.8Market Cap: ₹1.5K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→NGL Fine-Chem plans to expand its product portfolio to about 30 APIs by 2024 from around 22-23 currently.
→The market size for current products is approximately Rs. 1,500 crores, expected to grow to Rs. 2,300-2,500 crores with planned new products.
→Three new products in trial runs are anticipated to increase market size by Rs. 800-1,000 crores.
→Additional new products planned for this year and next 2-3 years will further expand the market opportunity.
→Sales volume growth has been impacted recently due to high prices and demand suppression but is expected to recover by Q4 of the current year.
→Capacity expansion (greenfield project) scheduled for commercial operation in FY25 to support higher volumes; capacity to rise by ~60%, adding Rs. 40-50 crores revenue.
→Historical market share gains expected to continue, especially in newer products where market share is still growing.

Margin guidance

Category 3

→Revenue growth expected from addition of 3 new products, potentially increasing market size by ₹800-1,000 crores (Page 14).
→Plan to expand product portfolio to 30 APIs by 2024, with new products contributing to market expansion (Pages 12-13).
→Capacity expansions delayed due to cost overruns and inflation; new greenfield CAPEX expected to complete in early 2024, ramping up revenues from FY25 (Pages 5-6, 10).
→Return on capital expected to remain stable over a 3-5 year horizon despite near-term challenges (Page 13).
→Current demand and margin pressure expected to ease gradually; gross margins may normalize within 3-4 quarters, with better pricing pass-through (Pages 6-7).
→Company aims to maintain leadership in core products and focus on expanding market share in next 10 products (Page 13).
→Overall optimism for veterinary pharma industry growth over next 4-5 years despite short-term cyclical challenges (Pages 8-9).

3 more insights locked — sign up free to unlock

Fundraise plans

→Current CAPEX of approximately Rs. 140 crores is being funded with a debt-to-internal accrual ratio of 2:1 (about 66.7% debt and 33.3% internal accruals).
→No explicit mention of new equity fundraising in the call.
→Greenfield expansion CAPEX delayed due to commodity price inflation; equipment ordering postponed to Nov 2022 with completion expected by early 2024 and commercial production ramp-up from FY25.
→Given the existing debt funding for the CAPEX and the deferred schedule, no immediate new fundraising beyond planned debt is indicated.
→Management did not explicitly mention plans for further debt or equity fundraising beyond current projects.

Order book

The transcript from the Q1 FY22-23 earnings call of NGL Fine-Chem Limited does not explicitly mention the current or expected order book or pending orders. However, key related highlights include: - Demand is currently subdued due to high prices and customers utilizing old inventory. - Some delay in demand normalization expected—a gentle recovery expected from Q3 FY23, with stronger recovery anticipated in Q4 FY23. - Pricing pressure and inflation have caused customers to resist price hikes, impacting orders. - A US customer places semi-annual orders; one shipment scheduled in Q2 FY23. - New products are under trial, expected to expand market size and order potential by Rs. 800 to 1,000 crores. - Capacity utilization is currently around 70%, with plans for expansion by FY25. No specific quantitative order book or pending order figures disclosed.

Capex plans

Yes

→NGL Fine-Chem is undertaking a greenfield expansion project at Tarapur.
→Original CAPEX estimate was Rs. 100 crores, revised to Rs. 140-150 crores due to inflation in raw material and steel prices.
→Equipment ordering for the greenfield expansion was initially scheduled for May 2022 but delayed to November 2022 due to high commodity prices.
→The new facility construction is expected to complete in early 2024, with commercial production ramp-up anticipated by Q2 FY25.
→The expansion is expected to increase capacity by approximately 60%, adding potential revenue of around Rs. 200 crores.
→CAPEX funding is planned at a 2:1 debt to internal accruals ratio.
→Additional investments include development of 3-4 new products this year, targeting a total product basket of about 30 APIs by 2024.
→Price pressures and inflation have delayed the expansion but management is monitoring to accelerate if costs ease.

How does NGL Fine Chem Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1NGL Fine Chem Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like NGL Fine Chem Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio